Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Korea and Singapore Regulators Sign Trade MOU For Drugs, Devices

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Korea's FDA and Singapore's Health Sciences Authority have signed a memorandum of understanding as part of their efforts to ensure the safety, quality and efficacy of health products traded between the two countries

You may also be interested in...



U.S. FDA Suggests Multi-layered Approach To Combat Counterfeit Drugs

SEOUL - U.S. FDA is encouraging regulatory counterparts in Asia Pacific Economic Cooperation forum countries to adopt a multi-layered approach to combat counterfeit drugs

More Talks Needed With China and Japan For Cooperation In Sharing Clinical Data - Korea FDA Official

SEOUL - Although drug regulatory officials from South Korea, Japan and China met in Beijing for two days from Dec. 17 in their second tri-party meeting, they failed to report "noticeable progress" in their pursuit of an integrated clinical trial data-sharing program and mutual acceptance of their rules and guidelines, according to Korea FDA

Korea Targets Biologics, Devices, Health Care Among Economic Growth Projects For Next Decade

SEOUL - South Korean President Lee Myung-bak named "17 new growth engines" at a science and technology council meeting at his office in Seoul Jan. 13. Expected to spearhead the country's economic growth for the next 10 years, of those 17 economic growth engines, the Korean government targeted biologics, medical devices and global health care among the national priorities

Latest Headlines
See All
UsernamePublicRestriction

Register

SC075098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel